Marc Voigt, CEO of Immutep (Previously Prima Biomed) speaking at Phar-East 2018, Singapore, 28Feb-2Mar

10 minutes with Marc Voigt, CEO of Immutep (Previously known as Prima Biomed)

Emily Event News Leave a Comment

Prima Biomed was originally built on CVac, a therapeutic cancer vaccine. With its recent shift to embrace multiple products, the company has decided to rebrand itself to Immutep, named after a subsidy acquired in 2014. Leading the company is Marc Voigt, who will join us at Phar-East 2018 to speak about their vision of the next big immune checkpoint in the immunotherapy race. …